Drug Profile

JMT 108

Alternative Names: JMT-108

Latest Information Update: 17 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai JMT-BIO Technology
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Interleukin 15 modulators; Programmed cell death 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Dec 2025 Shanghai JMT-Bio plans phase I/II in Malignant melanoma (Second-line therapy and greater, Unresectable, Late-stage disease, Metastatic disease) in December 2025 (IV) (NCT07280832)
11 Apr 2025 Phase-I clinical trials in Cancer (Late-stage disease) in China (IV) (NCT06877650)
08 Apr 2025 the US Food and Drug Administration (US FDA) approves clinical trial application for JMT 108 in Cancer in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com